**Core tip:** In this study, we analyzed the histological responses of colorectal liver metastasis from 74 responders and 76 non-responders after neoadjuvant chemotherapy. We identified that the absence of a radiological response and extended neoadjuvant chemotherapy, comprising more than seven treatment sessions, are the two most pertinent predictive factors of non-histological response. This study also confirmed that the histological response of colorectal liver metastases after neoadjuvant chemotherapy has an influence on survival and, hence, warrants consideration. However, this influence on overall survival was lacking in cases of particularly aggressive disease that revealed microscopic vascular invasion in histological analyses.

INTRODUCTION
============

Colorectal cancer is the third most common cancer in men and the second most common in women worldwide\[[@B1]-[@B6]\]. Almost a third of the patients have or will develop colorectal liver metastases (CRLMs)\[[@B2],[@B7],[@B8]\]. Only 20% of these patients are amenable to curative treatment by liver resection and/or thermo-ablation\[[@B7],[@B9],[@B10]\]. According to the most recent series, when combined with chemotherapy, this can result in a 5-year survival rate of up to 60%\[[@B6],[@B11]-[@B13]\].

Neoadjuvant chemotherapy (NAC) has recently become nearly systematic prior to surgical management of CRLMs\[[@B7],[@B14]-[@B16]\]. It can be administered to patients who are initially considered to be non-resectable, and to patients with liver disease that is at the limit of resectability\[[@B14],[@B17]-[@B19]\], while it is also used in cases of CRLMs that are initially resectable\[[@B20],[@B21]\]. The response to NAC is evaluated by radiological imaging, according to morphological criteria such as RECIST, mRECIST, and CHOI\[[@B22]-[@B28]\]. Surgery is mostly indicated in the case of liver lesions that are responsive to NAC, or for lesions that remain stable. Indeed, progression of the disease is a poor prognostic factor, and sometimes results in a temporary postponement of liver ablation surgery\[[@B15],[@B28],[@B29]\]. More recently, the response to NAC has also been evaluated based on histological criteria of the resected specimen. Rubbia-Brandt and Blazer scores indicate that histological regression correlates with the overall and disease-free survival (DFS) of patients after resection\[[@B13],[@B30],[@B31]\]. The most commonly used score in the world is the one established by Rubbia-Brandt and his team\[[@B31]\]. It reflects the tumor regression grade (TRG), which takes into account the level of necrosis and fibrosis, as well as the number of viable tumor cells. Few studies to date have documented the influence of TRG on patient survival, and these were mostly published by the authors of the scoring systems. This explains why the histological regression score of CRLM specimens is rarely used in current practice\[[@B15],[@B32]\]. Therefore, at present, analysis of the histological response (HR) by the TRG has no influence on whether or not adjuvant chemotherapy is administered. To our knowledge, no study has attempted to identify the predictive factors of HR after NAC.

This study aimed to analyze the HR, according to the Rubbia-Brandt TRG, on CRLM surgery performed after NAC. It also sought to identify independent predictive factors of a good response, and to analyze the influence of this response on DFS and overall.

MATERIALS AND METHODS
=====================

Patient inclusion
-----------------

From January 2006 to December 2013, patients who underwent surgery for CRLMs after NAC in our department were included. They were retrospectively analyzed with regard to their pre-treatment characteristics. Patients for whom the primary tumor was resected or who had chemotherapy at another center were also included.

Patient groups
--------------

The patients were separated into two groups based on their HR, according to Rubbia-Brandt TRG. Based on their TRG, each patient was either assigned to the responder (R) group (TRG 1, 2, and 3) or to the non-responder (NR) group (TRG 4 and 5).

Data collected
--------------

For each patient, the following preoperative parameters were included prospectively: Age, body mass index, American Society of Anesthesiologists' score, history of liver surgery or a liver procedure (*e.g*., portal vein embolization or drainage), date when the metastases were discovered, the existence of extra-hepatic metastases, NAC (*e.g*., the number of treatment sessions and the types of chemotherapy), associated targeted therapy and type, radiological evaluation (*e.g*., the morphological criteria of the response to NAC according to RECIST, mRECIST or CHOI criteria\[[@B22]-[@B28]\]), two-stage hepatectomy, the surgical strategy proposed by the multidisciplinary team meeting, the location of the primary, the treatment date, and the lymphatic status of the primary tumor. Perioperative parameters included: The types of procedures and number of segments resected. The postoperative parameters included: The length of hospitalization, occurrence of a severe or mild (according to the Clavien-Dindo classification) medical or surgical complication, mortality at 30 d, repeat procedures, initiation of postoperative chemotherapy, and the type of chemotherapy. The histological data comprised: The TRG, number of lesions on the resected specimens, resection margins (a resection was considered to be R0 when the smallest microscopic margin was more than or equal to 1 mm), presence of emboli, tumor differentiation grade, and size of the largest metastasis. The follow-up data comprised: The most recent update and status, date of death (if applicable), date of recurrence (if any) and its location.

Multidisciplinary team meeting
------------------------------

The patients' records were assessed at a multidisciplinary team meeting that included at least one radiologist, one liver surgeon, one digestive oncologist and one pa-thologist.

Surgical treatment
------------------

The minimal time period between the end of NAC and the surgery was 4 to 6 wk. Surgical resections were anatomical or non-anatomical (atypical resections), and combined or not combined with perioperative radiofrequency ablation (RFA) according to the rules regarding size and localization for this method. Surgical resections were performed in one or two steps irrespective of the strategy chosen (*i.e*., conventional, liver-first, or combined). Surgical resections were most often performed by laparotomy, and occasionally by laparoscopy if the anatomical and oncological conditions suited this approach. A perioperative ultrasound scan was systematically carried out to explore the liver disease, and it was used to guide the identification of the hepatectomy cuts in order to obtain an adequate margin. In the case of RFA, this was done perioperatively by two of our hospital\'s experienced radiologists. Ultrasound with a contrast agent (SonoVue) was sometimes used in case of difficulty viewing the anatomical area.

Histological analysis
---------------------

All of the histology slides were re-evaluated in a blind manner by the same specialized pathologist. The slides had already been fixed, embedded in paraffin, cut, spread, and colored according to standard pathology methods. These slides were microscopically analyzed according to the Rubbia-Brandt TRG score. For the resected specimens that had several tumors, and in case of a dissociated response, the worst TRG was taken into account. The following criteria were also analyzed: The existence of a "dangerous halo", thickness of the invasive front, ablation margin, degree of tumor differentiation, and presence of vascular emboli.

Ethics statement
----------------

Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

Statistical analysis
--------------------

The search for factors predictive of the response rate was based on percentage comparison tests (chi-squared or Fisher's exact tests, according to the theoretical sizes) for the qualitative variables, and on comparison of means (Student's *t*-test, in case of normalcy and equality of the variances) or distribution tests (the Mann-Whitney non-parametric test) for the quantitative variables. The predictive factors associated with the response at a threshold of 20% in the univariate analysis were introduced in this logistic regression model. The final model including the variables that were significantly and independently associated with the response rate was obtained by stepwise regression. The intermediate nested models were compared using the likelihood ratio test. The interactions between the independent variables of the final model were identified (they were all non-significant). The adequacy of the model for the data was tested. The degree of significance was set as *P* \< 0.05. Firstly, the analysis of TRG impact on overall survival (OS) was based on a bivariate comparison of Kaplan-Meier survival curves using the log-rank test. The survival curves were described with the use of the survival median (and the interquartile range) and hazard ratio (confidence interval at 95%) based on a Cox model. Secondly, the analysis of the independent influence of TRG on OS was based on a Cox model adjusted according to other predictive factors. The predictive factors (excluding recurrence) associated with OS at the threshold of 20% in the univariate analysis were jointly introduced with the TRG in this Cox model. The final model, including the variables that were significantly and independently associated with OS, was obtained by the stepwise regression method. The intermediate nested models were compared using the likelihood ratio test. The interactions between the TRG and the independent variables of the final model were identified (in particular, the interaction between the TRG and postoperative chemotherapy was identified and, if necessary, this was done during the stepwise regression procedure). The level of significance was set at 5% (*P* \< 0.05). The conditions for application (log-linearity and proportional risks) of the Cox model were verified. The quantitative variables were dichotomized by the median.

RESULTS
=======

Between January 2006 and December 2013, 521 liver resections for CLRM were carried out in our department. During this period, 150 patients underwent a liver resection for synchronous colon or rectal cancer liver metastases after NAC. Of these 150 patients, 74 (49%) were responders (R) and 76 (51%) were non-responders (NR) based on the resected specimen.

Preoperative characteristics
----------------------------

As shown in Table [1](#T1){ref-type="table"}, 75% of the patients had synchronous liver metastases. Sixty-three percent of the patients had a bilobar distribution of the lesions, with an average of 4 ± 3 lesions. The location of the primary tumor had a significant influence on the HR, which was better for the tumors of rectal origin: 47.3% *vs* 25%. The presence of a radiological response to NAC was significantly associated with a good HR. In 94% of the cases, NAC included 5-fluorouracil, in 72% it included irinotecan, and for 43% of the patients it included oxaliplatin. In the majority of cases (69%), chemotherapy was combined with a targeted therapy, without this having any statistically significant effect on the HR. However, when the type of targeted therapy was examined, it was noted that the use of bevacizumab led to a greater HR: 58% *vs* 43%. The number of NAC treatment sessions was significantly related to the HR, and the patients who were classified as R had a median number of six treatment sessions, which is fewer than for the NR patients. The patients for whom the treatment strategy comprised a liver-first procedure (*i.e*., the liver resected first in case of synchronous liver metastases with the primary tumor left in place) had a significantly better HR rate. However, the patients who underwent repeat liver resections were more often histologically non-responsive.

###### 

Preoperative criteria

                                              **NR**                               **R**                                ***P*-value**   **Total**
  ------------------------------------------- ------------------------------------ ------------------------------------ --------------- --------------------------------------
  Gender                                                                                                                                
  F                                           33 (43.4)                            38 (51.4)                            0.33            71 (47.3)
  M                                           43 (56.6)                            36 (48.6)                                            79 (52.7)
  Age, in yr                                                                                                                            
  Median                                      63[1](#T1FN1){ref-type="table-fn"}   64[1](#T1FN1){ref-type="table-fn"}   0.91            63.3[1](#T1FN1){ref-type="table-fn"}
  ASA                                                                                                                                   
  1                                           3 (3.9)                              4 (5.4)                              0.33            7 (4.7)
  2                                           70 (92.1)                            70 (94.6)                                            140 (93.3)
  3                                           3 (3.9)                              0 (0)                                                3 (2)
  Number of lesions before treatment                                                                                                    
  Median                                      3[1](#T1FN1){ref-type="table-fn"}    3[1](#T1FN1){ref-type="table-fn"}    0.35            3[1](#T1FN1){ref-type="table-fn"}
  Bilobar lesions                                                                                                                       
  No                                          26 (34.2)                            30 (40.5)                            0.42            56 (37.3)
  Yes                                         50 (65.8)                            44 (59.5)                                            94 (62.7)
  Synchronous liver metastases                                                                                                          
  No                                          21 (27.6)                            17 (23)                              0.51            38 (25.3)
  Yes                                         55 (72.4)                            57 (77)                                              112 (74.7)
  Metachronous livers metastases                                                                                                        
  No                                          55 (72.4)                            57 (77)                              0.51            112 (74.7)
  Yes                                         21 (27.6)                            17 (23)                                              38 (25.3)
  Time period if metachronous, in mo                                                                                                    
  Median                                      14[1](#T1FN1){ref-type="table-fn"}   15[1](#T1FN1){ref-type="table-fn"}   0.96            14[1](#T1FN1){ref-type="table-fn"}
  Extra-hepatic metastases                                                                                                              
  N                                           56 (73.7)                            57 (77)                              0.63            113 (75.3)
  Yes                                         20 (26.3)                            17 (23)                                              37 (24.7)
  Primary cancer                                                                                                                        
  Colon                                       57 (75.0)                            39 (52.7)                            0.004           96 (64)
  Rectum                                      19 (25.0)                            35 (47.3)                                            54 (36)
  N+ status primary tumor                                                                                                               
  No                                          20 (28.2)                            27 (37)                              0.26            47 (32.6)
  Yes                                         51 (71.8)                            46 (63)                                              97 (67.4)
  Cytotoxic chemotherapy                                                                                                                
  5-FU                                        72 (94.7)                            69 (93.2)                            0.74            141 (94)
  Oxaliplatin                                 33 (43.4)                            31 (41.9)                            0.85            64 (42.7)
  Irinotecan                                  54 (71.1)                            54 (73)                              0.79            108 (72)
  Capecitabine                                1 (1.3)                              1 (1.4)                              1               2 (1.3)
  Raltitrexed                                 0 (0.0)                              1 (1.4)                              0.49            1 (0.7)
  Targeted preoperative therapy                                                                                                         
  No                                          24 (31.6)                            23 (31.1)                            0.95            47 (31.3)
  Yes                                         52 (68.4)                            51 (68.9)                                            103 (68.7)
  Type of targeted therapy                                                                                                              
  None                                        24 (31.6)                            23 (31.1)                            0.056           47 (31.3)
  Bevacizumab                                 33 (43.4)                            43 (58.1)                                            76 (50.7)
  Cetuximab                                   17 (22.4)                            6 (8.1)                                              23 (15.3)
  Panitumumab                                 1 (1.3)                              2 (2.7)                                              3 (2)
  Aflibercept                                 1 (1.3)                              0 (0)                                                1 (0.7)
  Number of preoperative treatment sessions                                                                                             
  Median                                      8\*                                  6\*                                  0.038           7.5\*
  Response to preoperative chemotherapy                                                                                                 
  No                                          25 (32.9)                            13 (17.6)                                            38 (25.3)
  Yes                                         51 (67.1)                            61 (82.4)                            0.031           112 (74.7)
  Liver-first strategy                                                                                                                  
  No                                          74 (97.4)                            61 (82.4)                            0.002           135 (90)
  Yes                                         2 (2.6)                              13 (17.6)                                            15 (10)
  Combined surgery                                                                                                                      
  No                                          72 (94.7)                            68 (91.9)                            0.53            140 (93.3)
  Yes                                         4 (5.3)                              6 (8.1)                                              10 (6.7)
  Two-stage procedure                                                                                                                   
  No                                          54 (71.1)                            60 (81.1)                            0.15            114 (76)
  Yes                                         22 (28.9)                            14 (18.9)                                            36 (24)
  Repeat hepatectomy                                                                                                                    
  No                                          63 (82.9)                            69 (93.2)                            0.051           132 (88)
  Yes                                         13 (17.1)                            5 (6.8)                                              18 (12)
  Hepatectomy                                                                                                                           
  Minor                                       39 (51.3)                            33 (44.6)                            0.41            72 (48)
  Major                                       37 (48.7)                            41 (55.4)                                            78 (52)

Median. NR: Non-responders; R: Responders; F: Female; M: Male; ASA: American Society of Anes-thesiologist's score; 5-FU: 5-Fluorouracil.

Pathological characteristics
----------------------------

The median number of lesions found on the resected specimens was three (1.0--4.0). The rate of resection with healthy margins (R0) was 78%. There were multiple lesions in 72% of the cases. In the group of patients classified as R, there were significantly more homogeneous HR, fewer R1 resections, and fewer vascular neoplastic microemboli (VNME) (Table [2](#T2){ref-type="table"}).

###### 

Pathological criteria

                                           **NR**                                **R**                               ***P*-value**   **Total**
  ---------------------------------------- ------------------------------------- ----------------------------------- --------------- -----------------------------------
  Dissociated histological response                                                                                                  
  No                                       33 (43.4)                             55 (74.3)                           0.0001          88 (58.7)
  Yes                                      43 (56.6)                             19 (25.7)                                           62 (41.3)
  Number of lesions on specimen                                                                                                      
  Median                                   3[1](#T2FN1){ref-type="table-fn"}     2[1](#T2FN1){ref-type="table-fn"}   0.07            3[1](#T2FN1){ref-type="table-fn"}
  Lesions on specimen                                                                                                                
  Single                                   18 (23.7)                             24 (32.4)                           0.23            42 (28)
  Multiple                                 58 (76.3)                             50 (67.6)                                           108 (72)
  Lesions on specimen                                                                                                                
  ≤ 3                                      46 (60.5)                             53 (71.6)                           0.15            99 (66)
  \> 3                                     30 (39.5)                             21 (28.4)                                           51 (34)
  Resection                                                                                                                          
  R0                                       52 (68.4)                             65 (87.8)                           0.004           117 (78)
  R1                                       24 (31.6)                             9 (12.2)                                            33 (22)
  Emboli                                                                                                                             
  No                                       60 (78.9)                             68 (91.9)                           0.025           128 (85.3)
  Yes                                      16 (21.1)                             6 (8.1)                                             22 (14.7)
  Size of the largest metastasis                                                                                                     
  Median                                   2.9[1](#T2FN1){ref-type="table-fn"}   3[1](#T2FN1){ref-type="table-fn"}   0.43            3[1](#T2FN1){ref-type="table-fn"}
  Differentiation                                                                                                                    
  Unclassifiable                           2 (2.6)                               5 (6.8)                             0.45            7 (4.7)
  Undifferentiated/barely differentiated   5 (6.6)                               3 (4.1)                                             8 (5.3)
  Moderately differentiated                30 (39.5)                             34 (45.9)                                           64 (42.7)
  Well-differentiated                      39 (51.3)                             32 (43.2)                                           71 (47.3)

Median; NR: Non-responders; R: responders.

Postoperative characteristics
-----------------------------

The postoperative mortality was 0.7% (one patient died of hepatocellular insufficiency), with a complication rate of 38% (Table [3](#T3){ref-type="table"}). The average length of the hospital stay was 12.5 ± 7 d. Postoperative chemotherapy was administered to 55% of the patients, and in 83% of these cases, the chemotherapy protocol was similar to the one administered preoperatively. There was no significant difference between the R group and the NR group in terms of the choice of chemotherapy type. Regardless of the location, the tumor recurred in 89% of the cases. NR patients had significantly more recurrences in the liver.

###### 

Postoperative criteria

                                  **NR**                               **R**                                ***P*-value**   **Total**
  ------------------------------- ------------------------------------ ------------------------------------ --------------- ------------------------------------
  Complication                                                                                                              
  No                              45 (59.2)                            48 (64.9)                            0.48            93 (62)
  Yes                             31 (40.8)                            26 (35.1)                                            57 (38)
  Medical complication                                                                                                      
  No                              53 (69.7)                            54 (73)                              0.66            107 (71.3)
  Yes                             23 (30.3)                            20 (27)                                              43 (28.7)
  Surgical complication                                                                                                     
  No                              57 (75)                              61 (82.4)                            0.27            118 (78.7)
  Yes                             19 (25)                              13 (17.6)                                            32 (21.3)
  Length of the hospitalization                                                                                             
  Median                          11[1](#T3FN1){ref-type="table-fn"}   11[1](#T3FN1){ref-type="table-fn"}   0.36            11[1](#T3FN1){ref-type="table-fn"}
  Postoperative chemotherapy                                                                                                
  Absent                          36 (47.4)                            31 (41.9)                            0.33            67 (44.7)
  Similar                         31 (40.8)                            38 (51.4)                                            69 (46)
  Different                       9 (11.8)                             5 (6.8)                                              14 (9.3)
  Recurrence                                                                                                                
  No                              5 (6.6)                              12 (16.2)                            0.06            17 (11.3)
  Yes                             71 (93.4)                            62 (83.8)                                            133 (88.7)
  Recurrence                                                                                                                
  Hepatic                         59 (77.6)                            39 (52.7)                            0.001           98 (65.3)
  Extra-hepatic                   51 (67.1)                            46 (62.2)                            0.53            97 (64.7)
  Multiple sites                  43 (56.6)                            33 (44.6)                            0.14            76 (50.7)

Median. NR: Non-responders; R: responders.

Predictive factors of the histological response
-----------------------------------------------

The multivariate analysis identified five predictive factors of HR. Three were predictive of non-response (NR): More than seven NAC sessions, the absence of a radiological response after NAC, and a repeat hepatectomy. Two were predictive of a good response (R): Rectal origin of the primary tumor and liver-first strategy (Table [4](#T4){ref-type="table"}).

###### 

Predictive factors of the histological response

                                                       **Odds ratio**   **95%CI**         ***P*-value**
  ---------------------------------------------------- ---------------- ----------------- ---------------
  Number of preoperative treatment sessions                                               
  ≤ 7                                                  1                \-                \-
  \> 7                                                 0.47             \[0.23; 0.98\]    0.044
  Radiological response to preoperative chemotherapy                                      
  Yes                                                  1                \-                \-
  No                                                   0.33             \[0.14; 0.79\]    0.013
  Liver-first strategy                                                                    
  No                                                   1                \-                \-
  Yes                                                  5.11             \[1.06; 24.73\]   0.042
  Repeat hepatectomy                                                                      
  No                                                   1                \-                \-
  Yes                                                  0.30             \[0.09; 0.97\]    0.045
  Primary cancer                                                                          
  Colon                                                1                \-                \-
  Rectal                                               2.81             \[1.28; 6.14\]    0.010

Survival and prognostic factors
-------------------------------

The median survival of the patients was 6 yr (ranging from 4--7.5 yr).

**Overall survival:** The OS rates at 3 yr and 5 yr were 57% and 36%, respectively. These OS rates were significantly better for patients with an HR (the R group): 65% and 45%, respectively, *vs* 47% and 26%, respectively, for the NR group (Figure [1](#F1){ref-type="fig"}). The identification of independent prognostic factors of OS (Table [5](#T5){ref-type="table"}) revealed that the effect of HR was dependent on the presence or absence of VNME. In patients without VNME, HR was an independent prognostic factor of OS, while this was no longer the case in the presence of VNME upon analysis of the ablated specimen. Other factors that were prognostic of poor OS were: Male gender, preoperative targeted therapy, a two-stage hepatectomy protocol, and a N+ status of the primary tumor.

![Influence of the histological response on overall survival. TRG: Tumor regression grade; R: Responders; NR: Non-responders.](WJGO-11-295-g001){#F1}

###### 

Prognostic factors of overall survival

  **No vascular neoplastic microemboli on histology**                                                
  -------------------------------------------------------------- ------------------ ---------------- ---------------
  Responder                                                                                          
  NR                                                             1                  \[0.35; 0.86\]   0.010
  R                                                              0.55                                
  Gender                                                                                             
  F                                                              1                  \[1.11; 2.58\]   0.014
  M                                                              1.70                                
  Targeted preoperative therapy                                                                      
  No                                                             1                  \[1.40; 3.62\]   0.001
  Yes                                                            2.25                                
  Two-stage procedure                                                                                
  No                                                             1                  \[1.18; 3.06\]   0.008
  Yes                                                            1.90                                
  N+ status of the primary tumor                                                                     
  No                                                             1                  \[1.10; 2.84\]   0.018
  Yes                                                            1.77                                
  **Presence of vascular neoplastic microemboli on histology**                                       
                                                                 **Hazard ratio**   **95%CI**        ***P*-value**
  Gender                                                                                             
  F                                                              1                  \[1.11; 2.58\]   0.014
  M                                                              1.70                                
  Targeted preoperative therapy                                                                      
  No                                                             1                  \[1.40; 3.62\]   0.001
  Yes                                                            2.25                                
  Two-stage procedure                                                                                
  No                                                             1                  \[1.18; 3.06\]   0.008
  Yes                                                            1.90                                
  N+ status of the primary tumor                                                                     
  No                                                             1                  \[1.10; 2.84\]   0.018
  Yes                                                            1.77                                

NR: Non-responders; R: responders; F: Female; M: Male.

**DFS:** The DFS rates at 3 yr and 5 yr were 14% and 11%, respectively. These DFS survival rates were significantly better for patients with HR (the R group): 19% and 11%, respectively, *vs* 9% and 5%, respectively, for the NR patients (Figure [2](#F2){ref-type="fig"}). The search for independent prognostic factors of DFS identified one good prognostic factor, which was the presence of HR with NAC (the R group, *P* = 0.013), and four poor prognostic factors: NAC with targeted therapy (*P* = 0.004), more than three preoperative metastases (*P* = 0.001), R1 resection (*P* = 0.022), and a size greater than 3 cm for the largest metastasis (*P* = 0.011).

![Influence of the histological response on disease-free survival. TRG: Tumor regression grade; R: Responders; NR: Non-responders.](WJGO-11-295-g002){#F2}

DISCUSSION
==========

Our work demonstrates that the HR of CRLMs operated on after NAC has a significant influence on OS and DFS, as evaluated by the Rubbia-Brandt score. In this population, the OS rate at 5 yr was equivalent to that stated in the literature, which varies from 18%-58%\[[@B8],[@B10]-[@B13],[@B33]-[@B40]\]. However, the DFS in this population was at the lower limit of that reported in the literature, which varies from 11%-37%\[[@B10],[@B35]-[@B39]\]. This can likely be explained by the particularly severe liver disease in our population of selected patients. Indeed, 75% of our patients had synchronous metastases, while in the literature this rate varies from 15%-50%\[[@B2],[@B7],[@B8],[@B38]\]. We noted HR in 49% of the patients (TRG 1 to 3), including five patients (7%) with complete tumor regression (TRG1). In research published in 2007, the Rubbia-Brandt team found a good HR rate of 27%-82%, which varied according to the chemotherapy protocol\[[@B31]\]. Viganò et al\[[@B13]\] had figures similar to ours, with a good HR (TRG 1 to 3) for 44% of the patients and complete tumor regression (TRG1) for 8% of the patients, as was the case with the series reported by Loupakis et al\[[@B41]\], with HR for 48% and complete tumor regression (TRG 1) for 14% of the patients. We used the Rubbia-Brandt score, as it was the first to define standardized histological criteria of response to NAC in cases of CRLMs, and also because of its use in the management of rectal cancers\[[@B42]\].

We identified five independent predictive factors of HR after NAC. Three factors were predictive of the absence of HR (more than seven NAC treatment sessions, the absence of a radiological response after NAC, and repeat hepatectomy). The high number of NAC treatment sessions is probably a reflection of tumor chemotherapy resistance. This factor likely indicates that the earlier the response (evaluated radiologically) (*i.e*., before the first seven treatment sessions), the greater the chances of a good associated HR. In the study by Viganò et al\[[@B13]\], the number of treatment sessions also appeared to be a predictive factor of HR based on multivariate analysis, with a better HR when there were fewer than six chemotherapy treatment sessions. The absence of a radiological response (*i.e*., stability or progression) after NAC is recognized as a major factor for cancelling or delaying surgery after NAC\[[@B20],[@B43]-[@B45]\]. The influence of a repeat hepatectomy on HR has not been reported in the literature to date. One of the explanations, aside from the actual severity of a liver recurrence after the first hepatectomy, could be a change in the chemotherapy sensitivity of the recurring tumor. In our series, rectal origin of the primary tumor was associated with a three-fold greater probability of having a good HR. We found two studies in the literature for which this location of the primary tumor was a poor prognostic factor of OS\[[@B46],[@B47]\]. It has also been reported that a primary tumor that originated in the ascending colon is a poor prognostic factor\[[@B48]-[@B53]\]. A liver-first strategy in case of synchronous CRLMs was a factor predictive of a good HR. This can probably be explained by the fact that only the patients who were radiological responders after NAC have access to this strategy. To our knowledge, only two studies in the literature, namely Viganò et al\[[@B13]\] and Pietrantonio et al\[[@B54]\], have examined the factors predictive of a HR of CRLMs, based on multivariate analysis involving 323 and 93 patients, respectively. Viganò et al\[[@B13]\] were able to identify four predictive factors of a good response, which were the combination of oxaliplatin and irinotecan, the radiological response, the largest lesion ≤ 5 cm, and a carcinoembryonic antigen level ≤ 5 ng/mL.

OS was influenced by the HR according to whether or not there were VNME on the resected specimen. In fact, in the absence of VNME, the HR is an independent factor of a good prognosis for OS. Although the impact of the HR on OS has already been reported in the literature\[[@B13],[@B41],[@B54]\] , this is the first time that it has been shown that its influence is abrogated by the presence of VNME on the resected specimen, which is a known factor of poor prognosis. Therefore, tumor aggressiveness as reflected by VNME appears to be a more significant determining factor than the HR for the OS prognosis of patients. Four other independent factors of poor prognosis for OS were identified: Male gender, use of targeted therapy, two-stage hepatectomy, and N+ status of the primary tumor. Male gender\[[@B40],[@B46],[@B47],[@B55]-[@B58]\] and a positive lymphatic status of the primary tumor\[[@B34],[@B58]-[@B61]\] are prognostic factors that have been reported in the literature. The administration of NAC with a targeted therapy, which was identified in our analysis, can be explained by the fact that bevacizumab was typically used (74% of the targeted therapies). This is the treatment of choice for mutant RAS tumors, which carry worse prognoses\[[@B59],[@B61]-[@B67]\]. In terms of the two-stage hepatectomies, this can be explained by the fact that 13% of our patients did not undergo the second stage of surgery due to progression of the tumor after the first procedure. These figures are comparable to those presented in the literature, which vary from 15%-31%\[[@B68]-[@B73]\].

DFS was significantly influenced by the HR, with 17% survival at 5 yr for the responders compared to 5% for the non-responders. A similar difference in DFS was found in the study by Rubbia-Brandt et al\[[@B31]\], with a three-fold better survival for the responders compared to the non-responders. Four independent factors of poor prognosis were identified: Use of neoadjuvant targeted therapy, more than three preoperative lesions, metastasis with a size greater than 3 cm, and R1 resection. The number and size of metastases\[[@B13],[@B35],[@B36],[@B38],[@B58],[@B74]\], and R1 resection\[[@B35],[@B36],[@B38],[@B75]-[@B77]\] are the typical factors of poor prognosis found in the literature.

In conclusion, this study confirmed that the HR of CRLMs after NAC has an influence on survival and, hence, warrants attention. We found, however, that this influence on OS was lacking in cases of particularly aggressive disease, with microscopic vascular invasion in the histological analysis. Two simple criteria enable the prediction of HR after NAC: More than seven treatment sessions and the absence of a radiological response.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Colorectal cancer is the third most common cancer in men and the second most common in women worldwide. Almost a third of the patients has or will develop liver metastases. Neoadjuvant chemotherapy (NAC) has recently become nearly systematic prior to surgery of colorectal livers metastases (CRLMs). The response to NAC is evaluated by radiological imaging according to morphological criteria. More recently, the response to NAC has been evaluated based on histological criteria of the resected specimen. The most often used score is the tumor regression grade (TRG), which considers the necrosis, fibrosis, and number of viable tumor cells.

Research motivation
-------------------

Few studies to date have documented the influence of TRG on patient survival, and they were mostly published by the authors of the scoring systems. This explains why the histological regression score of CRLM specimens is rarely used in current practice\[[@B15],[@B32]\]. Therefore, at present, analysis of the histological response by the TRG has no influence on whether or not adjuvant chemotherapy is administered. To our knowledge, no study has attempted to identify the predictive factors of histological response after NAC.

Research objectives
-------------------

Our research aimed to analyze the histological response, according to the Rubbia-Brandt TRG, on CRLM surgery performed after NAC. It also sought to identify independent predictive factors of a good response, and to analyze the influence of this response on overall and disease-free survival.

Research methods
----------------

From January 2006 to December 2013, 150 patients who had undergone surgery for CRLMs after NAC were included. The patients were separated into two groups based on their histological response, according to Rubbia-Brandt TRG. Based on their TRG, each patient was either assigned to the responder (R) group (TRG 1, 2, and 3) or to the non-responder (NR) group (TRG 4 and 5). All of the histology slides were re-evaluated in a blind manner by the same specialized pathologist. Univariate and multivariate analyses were performed.

Research results
----------------

Seventy-four patients were classified as responders and 76 as non-responders. The postoperative mortality rate was 0.7%, with a complication rate of 38%. Multivariate analysis identified five predictive factors of histological response. Three were predictive of non-response (NR): More than seven NAC sessions, absence of a radiological response after NAC, and repeat hepatectomy (*P* \< 0.005). Two were predictive of a good response (R): Rectal origin of the primary tumor and a liver-first strategy (*P* \< 0.005). The overall survival was 57% at 3 yr and 36% at 5 yr. The disease-free survival rates were 14% at 3 yr and 11% at 5 yr. Factors contributing to a poor prognosis for the DFS were: No histological response after NAC, largest metastasis \> 3 cm, more than three preoperative metastases, R1 resection, and the use of a targeted therapy with NAC (*P* \< 0.005).

Research conclusions
--------------------

The histological response of CRLMs after NAC has an influence on survival, hence warranting consideration. We found, however, that this influence on overall survival was lacking in cases of particularly aggressive disease, with microscopic vascular invasion upon histological analysis.

Research perspectives
---------------------

Two simple criteria enable the prediction of a histological response after NAC: More than seven treatment sessions and absence of a radiological response.
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